Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.

Abstract

BACKGROUND Chronic lymphocytic leukemia (CLL) is a disease of the lymphoid system, in which the most common therapy is fludarabine plus cyclophosphamide (FC). The addition of rituximab to FC has been used, a combination known as FCR. OBJECTIVES To perform a systematic review with meta-analysis of clinical trials between 2000 and 2012 comparing FC and FCR… (More)
DOI: 10.1016/j.critrevonc.2015.02.013

Topics

  • Presentations referencing similar topics